Confluence Launches CRISPR Cancer-Killing Platform

Company Confluence Genetics Event Type Platform launch with concurrent peer-reviewed scientific validation Modality CRISPR-based cancer therapy — Cas12a2 nuclease triggering collateral cleavage of DNA and RNA Platform Cas-CLEAR Indication Cancer, with lead programs in hepatocellular carcinoma; mechanism applicable to molecularly defined hematologic malignancies Summary Confluence…